AU2002319469B2 - Thienopyrimidinediones and their use in the modulation of autoimmune disease - Google Patents

Thienopyrimidinediones and their use in the modulation of autoimmune disease Download PDF

Info

Publication number
AU2002319469B2
AU2002319469B2 AU2002319469A AU2002319469A AU2002319469B2 AU 2002319469 B2 AU2002319469 B2 AU 2002319469B2 AU 2002319469 A AU2002319469 A AU 2002319469A AU 2002319469 A AU2002319469 A AU 2002319469A AU 2002319469 B2 AU2002319469 B2 AU 2002319469B2
Authority
AU
Australia
Prior art keywords
methyl
dione
thieno
hydroxyisoxazolidin
ylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002319469A
Other languages
English (en)
Other versions
AU2002319469B8 (en
AU2002319469A1 (en
Inventor
Martin Edward Cooper
Simon David Guile
Anthony Howard Ingall
Rukhsana Tasneem Rasul
Rachel Heulwen Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002319469B8 publication Critical patent/AU2002319469B8/en
Publication of AU2002319469A1 publication Critical patent/AU2002319469A1/en
Application granted granted Critical
Publication of AU2002319469B2 publication Critical patent/AU2002319469B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
AU2002319469A 2001-07-28 2002-07-24 Thienopyrimidinediones and their use in the modulation of autoimmune disease Ceased AU2002319469B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0118479.5A GB0118479D0 (en) 2001-07-28 2001-07-28 Novel compounds
GB0118479.5 2001-07-28
PCT/GB2002/003399 WO2003011868A1 (en) 2001-07-28 2002-07-24 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Publications (3)

Publication Number Publication Date
AU2002319469B8 AU2002319469B8 (en) 2003-02-17
AU2002319469A1 AU2002319469A1 (en) 2003-05-29
AU2002319469B2 true AU2002319469B2 (en) 2007-08-09

Family

ID=9919407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319469A Ceased AU2002319469B2 (en) 2001-07-28 2002-07-24 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Country Status (24)

Country Link
US (2) US7384950B2 (https=)
EP (1) EP1414825B9 (https=)
JP (1) JP4456364B2 (https=)
KR (1) KR100897469B1 (https=)
CN (1) CN1324033C (https=)
AR (1) AR038000A1 (https=)
AT (1) ATE374204T1 (https=)
AU (1) AU2002319469B2 (https=)
BR (1) BR0211262A (https=)
CA (1) CA2453274A1 (https=)
DE (1) DE60222671T2 (https=)
ES (1) ES2292784T3 (https=)
GB (1) GB0118479D0 (https=)
HU (1) HUP0402336A3 (https=)
IL (2) IL159785A0 (https=)
IS (1) IS2598B (https=)
MX (1) MXPA04000677A (https=)
MY (1) MY138145A (https=)
NO (1) NO328713B1 (https=)
NZ (1) NZ530495A (https=)
PL (1) PL211351B1 (https=)
RU (1) RU2294937C9 (https=)
WO (1) WO2003011868A1 (https=)
ZA (1) ZA200400574B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) * 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US7550602B1 (en) 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CN101076335A (zh) * 2004-08-18 2007-11-21 默克公司 有丝分裂驱动蛋白抑制剂
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
AR070220A1 (es) * 2008-01-22 2010-03-25 Boehringer Ingelheim Int Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos
PT2411395E (pt) * 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP5990980B2 (ja) * 2012-04-02 2016-09-14 大日本印刷株式会社 オランザピンの中間体の製造方法
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AR117469A1 (es) 2018-12-21 2021-08-11 Merck Patent Gmbh Derivados de alquino disustituidos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
IL136499A0 (en) 1997-12-05 2001-06-14 Astrazeneca Uk Ltd Astrazeneca Pyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pypyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pyridazinone compounds, process for their preparatioridaziones compounds, process for their preparation, pharmaceutical compositions containing them, a n, pharmaceutical compositions containing them, a process for prepating the pharmaceutical compositiprocess for preparing the pharmaceutical compositions, and use thereof ons, and use thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ATE253580T1 (de) * 1998-08-28 2003-11-15 Astrazeneca Ab Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
RU2332420C2 (ru) 2003-01-17 2008-08-27 Астразенека Аб Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания

Also Published As

Publication number Publication date
DE60222671D1 (de) 2007-11-08
NO20040364L (no) 2004-03-29
IL159785A (en) 2009-11-18
EP1414825B9 (en) 2009-09-16
RU2294937C2 (ru) 2007-03-10
CN1538970A (zh) 2004-10-20
MY138145A (en) 2009-04-30
PL211351B1 (pl) 2012-05-31
US20080207642A1 (en) 2008-08-28
NO328713B1 (no) 2010-05-03
RU2004102392A (ru) 2005-07-10
CA2453274A1 (en) 2003-02-13
IS7118A (is) 2004-01-19
IL159785A0 (en) 2004-06-20
ES2292784T3 (es) 2008-03-16
AU2002319469B8 (en) 2003-02-17
NZ530495A (en) 2005-07-29
DE60222671T2 (de) 2008-06-26
BR0211262A (pt) 2004-07-20
JP2004538316A (ja) 2004-12-24
HUP0402336A3 (en) 2008-09-29
JP4456364B2 (ja) 2010-04-28
CN1324033C (zh) 2007-07-04
WO2003011868A1 (en) 2003-02-13
HK1065785A1 (en) 2005-03-04
PL369232A1 (en) 2005-04-18
HUP0402336A2 (hu) 2005-02-28
US7384950B2 (en) 2008-06-10
KR100897469B1 (ko) 2009-05-14
US20040254198A1 (en) 2004-12-16
ATE374204T1 (de) 2007-10-15
IS2598B (is) 2010-03-15
ZA200400574B (en) 2005-04-26
AR038000A1 (es) 2004-12-22
EP1414825A1 (en) 2004-05-06
RU2294937C9 (ru) 2007-07-20
MXPA04000677A (es) 2004-04-05
KR20040017355A (ko) 2004-02-26
EP1414825B1 (en) 2007-09-26
GB0118479D0 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
AU2002319469B2 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
US7361660B2 (en) Chemical compounds
AU2002319469A1 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
AU2004206012B2 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
AU763758B2 (en) Novel compounds
US20080221131A1 (en) Thienopyrimidinediones and their use in modulation of autoimmune disease
HK1065785B (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
HK1065542B (en) THIENO(2,3-d)PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS SPROLIFERATION
ZA200505227B (en) Thienopyridazinones and their use in modulation of autoimmune disease

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 21, NO 31, PAGE(S) 3616 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2002319469, UNDER INID (72), CORRECT THE NAME OF THE CO-INVENTOR TO READ RASUL, RUKHSANA, TASNEEM

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired